Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![VistaPResearch Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::402353316.png) Vista Partners LLC [@VistaPResearch](/creator/twitter/VistaPResearch) on x 7399 followers
Created: 2025-07-21 04:14:09 UTC

During the Phase 2b portion of the RESOLVE study, Eupraxia will continue to report additional data from patients that were entered into the open-label Phase 2a study, with further data from cohorts 5–8 available in early September & November of 2025
$EPRX

![](https://pbs.twimg.com/card_img/1945094851357499393/fz4ioulm?format=jpg&name=800x419)

XX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1947148063283495265/c:line.svg)

**Related Topics**
[$eprx](/topic/$eprx)
[vista](/topic/vista)

[Post Link](https://x.com/VistaPResearch/status/1947148063283495265)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

VistaPResearch Avatar Vista Partners LLC @VistaPResearch on x 7399 followers Created: 2025-07-21 04:14:09 UTC

During the Phase 2b portion of the RESOLVE study, Eupraxia will continue to report additional data from patients that were entered into the open-label Phase 2a study, with further data from cohorts 5–8 available in early September & November of 2025 $EPRX

XX engagements

Engagements Line Chart

Related Topics $eprx vista

Post Link

post/tweet::1947148063283495265
/post/tweet::1947148063283495265